{"product_id":"liver-surgery-for-breast-cancer-that-has-spread-to-the-liver-what-the-latest-research-shows","title":"Liver Surgery for Breast Cancer That Has Spread to the Liver: What the Latest Research Shows","description":"\u003cp\u003eWhen breast cancer spreads to the liver, doctors have long debated whether surgically removing the liver tumors can help patients live longer. This meta-analysis of 9 studies, including 1,732 patients, found a clear survival advantage for those who underwent liver resection (surgical removal of liver metastases). Patients who had surgery had a 31% lower risk of dying overall (hazard ratio 0.69) and significantly better survival at 1, 3, and 5 years compared to those treated without surgery. The authors stress that careful patient selection is essential and that randomized trials are needed to confirm these promising results.\u003c\/p\u003e\n\n\u003ch1\u003eLiver Surgery for Breast Cancer That Has Spread to the Liver: What the Latest Research Shows\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding the Problem: Breast Cancer and Liver Metastases\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why\"\u003eWhy Is There Uncertainty About Liver Surgery?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#studies\"\u003eThe 9 Studies Included in This Analysis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#results-1yr\"\u003eKey Finding: Survival at 1 Year\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#results-3yr\"\u003eKey Finding: Survival at 3 Years\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#results-5yr\"\u003eKey Finding: Survival at 5 Years\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#overall\"\u003eOverall Survival: The Big Picture\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA meta-analysis of 9 studies with 1,732 patients found liver resection improved overall survival in breast cancer liver metastases.\u003c\/li\u003e\n\u003cli\u003eSurgery was associated with a 31% lower risk of death over time compared with no surgery.\u003c\/li\u003e\n\u003cli\u003eFive-year survival was 46.0% with surgery versus 24.7% without surgery in this analysis.\u003c\/li\u003e\n\u003cli\u003eBenefits were seen in carefully selected patients, such as those with limited liver involvement and no extrahepatic disease.\u003c\/li\u003e\n\u003cli\u003eRandomized trials are still needed; this study does not prove surgery is superior for all patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding the Problem: Breast Cancer and Liver Metastases\u003c\/h2\u003e\n\n\u003cp\u003eBreast cancer is the most common cancer in women worldwide, with \u003cstrong\u003e2.3 million new diagnoses made in 2020\u003c\/strong\u003e alone. Thanks to improvements in early detection, personalized treatments, and better therapeutic strategies, many patients now have excellent outcomes — some can expect 5-year overall survival rates as high as 90%.\u003c\/p\u003e\n\n\u003cp\u003eYet breast cancer remains a serious threat. In 2021, more than \u003cstrong\u003e43,000 patients in the United States\u003c\/strong\u003e were expected to die from breast cancer. About \u003cstrong\u003e6–10% of patients\u003c\/strong\u003e already have metastatic disease (cancer that has spread to other organs) at the time of their initial diagnosis, and another \u003cstrong\u003e20–30% of patients\u003c\/strong\u003e diagnosed with early-stage disease will eventually develop distant metastases.\u003c\/p\u003e\n\n\u003cp\u003eThe liver is one of the most common sites where breast cancer spreads. In fact, the liver is the first site of distant metastasis in \u003cstrong\u003e1.0–8.0% of breast cancer cases\u003c\/strong\u003e. Historically, breast cancer with liver metastases (BCLM) has been associated with poor outcomes — the estimated 5-year overall survival rate after the cancer recurs in the liver is only \u003cstrong\u003e8.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIt's important to understand what \"metastatic\" means: when breast cancer cells travel through the bloodstream or lymphatic system to settle in another organ like the liver, the disease is considered stage 4 (metastatic) breast cancer. While it is not typically considered curable in the traditional sense, some patients can live for many years with modern treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"why\"\u003eWhy Is There Uncertainty About Liver Surgery?\u003c\/h2\u003e\n\n\u003cp\u003eSurgery to remove liver metastases has proven highly effective for another type of cancer: colorectal cancer (CRC). In patients with CRC that has spread to the liver, liver resection (also called hepatectomy) can be curative, and it is now recommended in the European Society for Medical Oncology (ESMO) guidelines whenever feasible.\u003c\/p\u003e\n\n\u003cp\u003eBut for breast cancer that has spread to the liver, there is \u003cstrong\u003eno widely accepted consensus\u003c\/strong\u003e on surgery. Major guideline groups have taken different positions:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe \u003cstrong\u003e4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4)\u003c\/strong\u003e state that local therapy (such as surgery) should only be proposed in very selected cases — specifically for patients with good performance status, limited liver involvement (no cancer outside the liver), and demonstrated control of disease after adequate systemic therapy.\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eNational Comprehensive Cancer Network (NCCN)\u003c\/strong\u003e guidelines, widely used in the United States, \u003cstrong\u003edo not recommend\u003c\/strong\u003e liver resection as an option for curative treatment of BCLM.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOnly about \u003cstrong\u003e1.8% of all liver resections\u003c\/strong\u003e performed are for breast cancer secondaries — a reflection of the medical community's hesitation. A major reason for this hesitation is that fewer than \u003cstrong\u003e8.0% of patients with metastatic breast cancer\u003c\/strong\u003e have disease confined only to the liver. If cancer has spread elsewhere in the body, removing just the liver tumors may seem less helpful.\u003c\/p\u003e\n\n\u003cp\u003eThis uncertainty means doctors lack clear guidance on which patients, if any, might truly benefit from liver surgery. The current study was designed to address this gap.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers performed a \u003cstrong\u003esystematic review and meta-analysis\u003c\/strong\u003e — a type of study that combines results from multiple existing studies to reach stronger conclusions than any single study alone. They followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE guidelines, which are internationally recognized standards for conducting this type of research.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe PICO framework\u003c\/strong\u003e was used to define the research question:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePopulation:\u003c\/strong\u003e Female patients aged 18 years or older with newly diagnosed breast cancer with liver metastases (BCLM), confirmed by histology or radiology.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntervention:\u003c\/strong\u003e Surgical resection (removal) of the liver metastasis with curative intent.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComparison:\u003c\/strong\u003e Patients treated for BCLM without surgical resection of the liver metastasis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOutcomes:\u003c\/strong\u003e Annual survival after BCLM diagnosis — specifically overall survival at 1, 3, and 5 years, as well as overall survival expressed as hazard ratios (HR).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAn electronic search was performed across \u003cstrong\u003ethree major medical databases\u003c\/strong\u003e: PubMed Medline, EMBASE, and Scopus. Two independent reviewers conducted the search using terms such as \"breast liver metastases,\" \"breast liver metastases resection,\" \"hepatic metastases,\" \"breast cancer survival,\" \"breast cancer,\" and \"hepatectomy.\" Only English-language studies were included, and the search was not restricted by year of publication. However, only studies published since \u003cstrong\u003e2013\u003c\/strong\u003e were included in the meta-analysis, because targeted therapies have revolutionized breast cancer management in recent years.\u003c\/p\u003e\n\n\u003cp\u003eThe final search was performed on \u003cstrong\u003eJuly 7, 2021\u003c\/strong\u003e. The initial search identified \u003cstrong\u003e2,618 studies\u003c\/strong\u003e. After removing \u003cstrong\u003e118 duplicates\u003c\/strong\u003e and \u003cstrong\u003e9 non-English papers\u003c\/strong\u003e, and screening titles, abstracts, and full texts, \u003cstrong\u003e9 studies\u003c\/strong\u003e meeting all inclusion criteria remained. These 9 studies were the focus of the meta-analysis.\u003c\/p\u003e\n\n\u003cp\u003eFor statistical analysis, survival data were expressed as odds ratios (OR) using the Mantel-Haenszel method. A hazard ratio (HR) — which measures how quickly death occurs over time — was calculated using the generic inverse variance method. All tests were two-tailed, with P values less than 0.050 considered statistically significant. Study quality was assessed using the Newcastle-Ottawa Scale.\u003c\/p\u003e\n\n\u003ch2 id=\"studies\"\u003eThe 9 Studies Included in This Analysis\u003c\/h2\u003e\n\n\u003cp\u003eThe 9 studies included data from \u003cstrong\u003e1,732 patients\u003c\/strong\u003e in total. Of these, \u003cstrong\u003e24.5% (424 patients)\u003c\/strong\u003e underwent surgical resection of their liver metastases, while \u003cstrong\u003e75.5% (1,308 patients)\u003c\/strong\u003e did not. Three of the 9 studies (33.3%) were prospective in design (following patients forward in time), while the remaining 6 (66.7%) were retrospective (looking back at medical records). Publication dates ranged from 2013 to 2020.\u003c\/p\u003e\n\n\u003cp\u003eThe studies came from around the world, including Italy, the United Kingdom, China, the United States, France, Germany, and the Czech Republic. All patients were female, with a mean age at diagnosis of \u003cstrong\u003e52.9 years (range 25–94 years)\u003c\/strong\u003e. There were 369 patients with synchronous disease (21.3%), meaning liver metastases were discovered within 6 months of the primary breast cancer diagnosis.\u003c\/p\u003e\n\n\u003cp\u003eHere is the breakdown of the individual studies:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStudy\u003c\/th\u003e\n    \u003cth\u003eCountry\u003c\/th\u003e\n    \u003cth\u003eDesign\u003c\/th\u003e\n    \u003cth\u003eSurgery (n)\u003c\/th\u003e\n    \u003cth\u003eNo Surgery (n)\u003c\/th\u003e\n    \u003cth\u003eAge\u003c\/th\u003e\n    \u003cth\u003eFollow-up\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePolistina 2013\u003c\/td\u003e\n    \u003ctd\u003eItaly\u003c\/td\u003e\n    \u003ctd\u003eRetrospective\u003c\/td\u003e\n    \u003ctd\u003e12\u003c\/td\u003e\n    \u003ctd\u003e14\u003c\/td\u003e\n    \u003ctd\u003e58 (mean)\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAbbas 2017\u003c\/td\u003e\n    \u003ctd\u003eUK\u003c\/td\u003e\n    \u003ctd\u003eRetrospective\u003c\/td\u003e\n    \u003ctd\u003e23\u003c\/td\u003e\n    \u003ctd\u003e38\u003c\/td\u003e\n    \u003ctd\u003e54 (median)\u003c\/td\u003e\n    \u003ctd\u003e48 months (median)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFeng 2020\u003c\/td\u003e\n    \u003ctd\u003eChina\u003c\/td\u003e\n    \u003ctd\u003eRetrospective\u003c\/td\u003e\n    \u003ctd\u003e65\u003c\/td\u003e\n    \u003ctd\u003e319\u003c\/td\u003e\n    \u003ctd\u003e50.9 (median)\u003c\/td\u003e\n    \u003ctd\u003e47 months (mean)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eChun 2020\u003c\/td\u003e\n    \u003ctd\u003eUSA\u003c\/td\u003e\n    \u003ctd\u003eRetrospective\u003c\/td\u003e\n    \u003ctd\u003e136\u003c\/td\u003e\n    \u003ctd\u003e763\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSadot 2016\u003c\/td\u003e\n    \u003ctd\u003eUSA\u003c\/td\u003e\n    \u003ctd\u003eRetrospective\u003c\/td\u003e\n    \u003ctd\u003e69\u003c\/td\u003e\n    \u003ctd\u003e98\u003c\/td\u003e\n    \u003ctd\u003e51 (median)\u003c\/td\u003e\n    \u003ctd\u003e31 months (mean)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMariani 2013\u003c\/td\u003e\n    \u003ctd\u003eFrance\u003c\/td\u003e\n    \u003ctd\u003eRetrospective\u003c\/td\u003e\n    \u003ctd\u003e51\u003c\/td\u003e\n    \u003ctd\u003e51\u003c\/td\u003e\n    \u003ctd\u003e50 (median)\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDittmar 2013\u003c\/td\u003e\n    \u003ctd\u003eGermany\u003c\/td\u003e\n    \u003ctd\u003eProspective\u003c\/td\u003e\n    \u003ctd\u003e34\u003c\/td\u003e\n    \u003ctd\u003e6\u003c\/td\u003e\n    \u003ctd\u003e53 (median)\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eWeinrich 2014\u003c\/td\u003e\n    \u003ctd\u003eGermany\u003c\/td\u003e\n    \u003ctd\u003eProspective\u003c\/td\u003e\n    \u003ctd\u003e21\u003c\/td\u003e\n    \u003ctd\u003e8\u003c\/td\u003e\n    \u003ctd\u003e55 (median)\u003c\/td\u003e\n    \u003ctd\u003e22 months (mean)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTreska 2014\u003c\/td\u003e\n    \u003ctd\u003eCzech Republic\u003c\/td\u003e\n    \u003ctd\u003eProspective\u003c\/td\u003e\n    \u003ctd\u003e13\u003c\/td\u003e\n    \u003ctd\u003e11\u003c\/td\u003e\n    \u003ctd\u003e50.9 (mean)\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eInformation on tumor type and hormone receptor status was available from several studies. Among those reporting this data, \u003cstrong\u003e285 patients had ductal carcinoma\u003c\/strong\u003e, 24 had lobular carcinoma, and 9 had other subtypes. Hormone receptor status was recorded as follows: \u003cstrong\u003e130 were estrogen receptor positive (ER+)\u003c\/strong\u003e, \u003cstrong\u003e83 were progesterone receptor positive (PR+)\u003c\/strong\u003e, and \u003cstrong\u003e66 were HER2 positive (HER2+)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"results-1yr\"\u003eKey Finding: Survival at 1 Year\u003c\/h2\u003e\n\n\u003cp\u003eOne year after diagnosis of liver metastases, patients who underwent surgery had \u003cstrong\u003esignificantly better overall survival\u003c\/strong\u003e than those who did not. In the surgery group, \u003cstrong\u003e92.5% (124 of 134 patients)\u003c\/strong\u003e were alive at 1 year, compared to \u003cstrong\u003e79.7% (311 of 390 patients)\u003c\/strong\u003e in the non-surgery group (P \u0026lt; 0.001).\u003c\/p\u003e\n\n\u003cp\u003eLooked at another way, the \u003cstrong\u003emortality rate\u003c\/strong\u003e (death rate) at 1 year was \u003cstrong\u003e7.5% (10 of 134)\u003c\/strong\u003e for surgical patients versus \u003cstrong\u003e20.3% (79 of 390)\u003c\/strong\u003e for non-surgical patients. When the results were pooled using meta-analysis, the odds of death were dramatically lower for the surgery group (\u003cstrong\u003eOR: 0.25, 95% CI: 0.08–0.74, P = 0.010\u003c\/strong\u003e). An odds ratio of 0.25 means the odds of dying within 1 year were \u003cstrong\u003e75% lower\u003c\/strong\u003e in the surgery group compared to the non-surgery group.\u003c\/p\u003e\n\n\u003cp\u003eStatistical heterogeneity between studies at this time point was low (I² = 32%), meaning the studies were reasonably consistent with each other, which strengthens confidence in this finding. Of note, one large study (Feng 2020) contributed 81.8% of the non-surgical patients at this time point.\u003c\/p\u003e\n\n\u003ch2 id=\"results-3yr\"\u003eKey Finding: Survival at 3 Years\u003c\/h2\u003e\n\n\u003cp\u003eAt 3 years after diagnosis of BCLM, the survival gap between the two groups was even more pronounced. Among patients who underwent liver resection, \u003cstrong\u003e81.9% (123 of 152)\u003c\/strong\u003e were still alive, compared to just \u003cstrong\u003e47.0% (197 of 419)\u003c\/strong\u003e in the non-surgery group (P \u0026lt; 0.001).\u003c\/p\u003e\n\n\u003cp\u003eThe mortality rates tell the same story: \u003cstrong\u003e19.1% (29 of 152)\u003c\/strong\u003e of surgical patients had died by 3 years, versus \u003cstrong\u003e53.0% (222 of 419)\u003c\/strong\u003e of non-surgical patients. When the investigators pooled the data at the meta-analysis level, however, the difference did not reach statistical significance — the odds ratio was 0.32 (95% CI: 0.09–1.12, P = 0.070).\u003c\/p\u003e\n\n\u003cp\u003eThis means that while individual studies showed a clear advantage for surgery, the combined statistical analysis could not definitively prove that surgery reduced 3-year mortality. There was substantial heterogeneity between studies at this time point (I² = 77%), meaning the studies differed considerably from each other — likely due to differences in patient populations, treatments, and study designs. One study (Feng 2020) accounted for 76.1% of the non-surgical patients at this time point.\u003c\/p\u003e\n\n\u003ch2 id=\"results-5yr\"\u003eKey Finding: Survival at 5 Years\u003c\/h2\u003e\n\n\u003cp\u003ePerhaps the most striking finding emerged at 5 years after diagnosis. Among patients who had liver resection, \u003cstrong\u003e46.0% (162 of 352)\u003c\/strong\u003e were alive at 5 years, compared to only \u003cstrong\u003e24.7% (309 of 1,249)\u003c\/strong\u003e in the non-surgery group (P \u0026lt; 0.001).\u003c\/p\u003e\n\n\u003cp\u003eIn terms of mortality, \u003cstrong\u003e54.0% (190 of 352)\u003c\/strong\u003e of surgical patients had died by 5 years, versus \u003cstrong\u003e75.3% (940 of 1,249)\u003c\/strong\u003e of non-surgical patients. The pooled meta-analysis confirmed a statistically significant survival benefit for surgery (\u003cstrong\u003eOR: 0.46, 95% CI: 0.25–0.87, P = 0.020\u003c\/strong\u003e) — meaning the odds of death at 5 years were \u003cstrong\u003e54% lower\u003c\/strong\u003e for those who underwent resection. Heterogeneity was moderate to high (I² = 70%).\u003c\/p\u003e\n\n\u003cp\u003eThe two largest studies — Feng 2020 and Chun 2020 — together accounted for \u003cstrong\u003e86.6% of the non-surgical patients\u003c\/strong\u003e at 5 years, meaning the results are heavily weighted toward the findings of these two well-conducted analyses.\u003c\/p\u003e\n\n\u003cp\u003eLooking at the individual studies at 5 years:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFeng 2020:\u003c\/strong\u003e 58.5% surgery survival vs. 27.9% non-surgery survival\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChun 2020:\u003c\/strong\u003e 52.9% vs. 21.0%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbbas 2017:\u003c\/strong\u003e 52.2% vs. 47.4%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSadot 2016:\u003c\/strong\u003e 37.7% vs. 38.8% (the only study showing no difference)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePolistina 2013:\u003c\/strong\u003e 33.3% vs. 14.3%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDittmar 2013:\u003c\/strong\u003e 26.5% vs. 16.7%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreska 2014:\u003c\/strong\u003e 7.7% vs. 9.1%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"overall\"\u003eOverall Survival: The Big Picture\u003c\/h2\u003e\n\n\u003cp\u003eWhen the researchers combined all survival data over the entire follow-up period (mean follow-up of \u003cstrong\u003e37 months\u003c\/strong\u003e), patients who underwent surgery had \u003cstrong\u003esignificantly better overall survival\u003c\/strong\u003e than those who did not. The pooled hazard ratio was \u003cstrong\u003e0.69 (95% CI: 0.59–0.80, P \u0026lt; 0.00001)\u003c\/strong\u003e, with low heterogeneity between studies (I² = 21%).\u003c\/p\u003e\n\n\u003cp\u003eWhat does a hazard ratio of 0.69 mean for patients? It means that at any given point during the follow-up period, patients who had liver resection were \u003cstrong\u003e31% less likely to die\u003c\/strong\u003e than those who did not have surgery. This is a clinically meaningful benefit — a substantial reduction in the risk of death over time.\u003c\/p\u003e\n\n\u003cp\u003eIt's important to understand, however, that this benefit is not universal. The 5-year survival rate of only 24.7% in the non-surgery group reflects what might be expected with systemic therapy alone in this patient population. Notably, the authors point out that in today's era of modern targeted treatments, patients with estrogen receptor (ER)-positive or HER2-positive metastatic disease can often expect their median survival to reach or even exceed 5 years. This suggests that the 24.7% 5-year survival in the control group may be lower than what some patients could achieve with modern systemic therapy — and underscores that the survival benefit of surgery needs to be weighed against the effectiveness of contemporary drug treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eSo what does this research mean for a patient facing a diagnosis of breast cancer that has spread to the liver? The findings suggest that \u003cstrong\u003esurgical removal of liver metastases may offer a realistic chance of long-term survival\u003c\/strong\u003e for carefully selected patients.\u003c\/p\u003e\n\n\u003cp\u003eBased on this and other research, the following factors appear to identify patients who may benefit most from liver resection:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNegative axillary lymph nodes\u003c\/strong\u003e at the time of breast surgery\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSolitary liver lesions\u003c\/strong\u003e (fewer tumors in the liver)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore than 24 months\u003c\/strong\u003e between the original breast cancer diagnosis and the appearance of liver metastases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eR0 hepatic resection\u003c\/strong\u003e — meaning the surgeon was able to remove the tumor completely with clear margins (no cancer cells left at the edge of the removed tissue)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo extrahepatic disease\u003c\/strong\u003e — cancer that has not spread beyond the liver is associated with better outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOn the flip side, patients with \u003cstrong\u003etriple-negative breast cancer\u003c\/strong\u003e appear to have poorer survival outcomes after surgery for BCLM, and higher numbers of metastatic lesions and younger age have also been associated with poorer outcomes. The authors note that extrahepatic disease is the single most important negative prognostic factor — one study of 34 patients found it was the \u003cstrong\u003eonly\u003c\/strong\u003e factor associated with reduced survival.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also highlight a key point about the control group: in this analysis, the 5-year overall survival for patients treated with systemic therapy alone was only 24.7%. This is an important context for treatment decisions, but it's also worth knowing that modern targeted therapies have improved outcomes, and some patients with ER+ or HER2+ disease will do much better than this historical average.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eEvery study has limitations, and the authors are transparent about theirs. Here are the most important ones to keep in mind:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo randomized controlled trials.\u003c\/strong\u003e None of the 9 included studies were randomized, meaning patients were not randomly assigned to surgery or no surgery. This introduces the risk of \u003cstrong\u003eselection bias\u003c\/strong\u003e — the possibility that patients who had surgery were healthier or had less aggressive disease to begin with, which could partly explain their better survival. The quality assessment confirmed a performance bias in all included studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeterogeneity between studies.\u003c\/strong\u003e There was significant variability between studies in terms of patient populations, treatment approaches, and study designs. This is reflected in the moderate-to-high I² values at the 3-year and 5-year time points.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVaried treatment strategies.\u003c\/strong\u003e The chemotherapy, hormonal therapy, and other treatments patients received varied across studies, and not all details were available. Some surgical patients received (neo)adjuvant chemotherapy and endocrine therapy; others had surgery alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMissing clinicopathological data.\u003c\/strong\u003e There was no data available to compare how patient age, gender, comorbidities, or hormone receptor status affected outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo data on recurrence or quality of life.\u003c\/strong\u003e Limited data was available on cancer recurrence after liver resection, and the cost-effectiveness of aggressive treatment strategies and their impact on quality of life were not addressed. The chance of achieving complete disease control is reported to be low in previous studies, and recovery from aggressive surgery can significantly impact quality of life.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIt's also important to note that \u003cstrong\u003ethere are currently no registered clinical trials\u003c\/strong\u003e exploring surgical resection of BCLM, which means prospective, randomized data is still missing from the evidence base.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations\u003c\/h2\u003e\n\n\u003cp\u003eBased on the findings of this meta-analysis, the authors offer the following guidance:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiver resection should be considered at multidisciplinary team (MDT) meetings\u003c\/strong\u003e for patients with breast cancer liver metastases. A multidisciplinary approach — involving surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists working together — is essential to weigh the potential benefits and risks for each individual patient.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJudicious patient selection is crucial.\u003c\/strong\u003e Surgery should not be offered to everyone, but rather to those who have the features associated with better outcomes — limited liver involvement, no (or stable) extrahepatic disease, good performance status, and disease that has responded to systemic therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients should have honest conversations with their oncologists\u003c\/strong\u003e about whether liver surgery is appropriate for their specific situation, taking into account their tumor biology (hormone receptor and HER2 status), the extent of their disease, and their overall health.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRandomized prospective trials are urgently needed.\u003c\/strong\u003e The authors call for validation of these results in the next generation of prospective, randomized studies to better guide clinical decision-making and to clarify which patients benefit most.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors emphasize that this study \u003cstrong\u003edoes not prove the superiority of surgery\u003c\/strong\u003e as an intervention in BCLM. Rather, it demonstrates the \u003cstrong\u003epragmatic role of surgery in improving overall survival in carefully selected patients\u003c\/strong\u003e — a meaningful distinction for patients and clinicians to understand when making treatment decisions.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, the key takeaway is hopeful but measured: liver resection for breast cancer metastases is a legitimate treatment option that may significantly extend life in the right circumstances. The decision should be personalized, made by an experienced multidisciplinary team, and based on a thorough evaluation of your specific cancer biology, overall health, and treatment goals.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWho might be a candidate for liver surgery when breast cancer spreads to the liver?\u003c\/h3\u003e\n\u003cp\u003eBased on this research, patients who may benefit most have limited liver involvement, cancer that has not spread beyond the liver, good performance status, and disease controlled after systemic therapy. Other favorable features include negative axillary lymph nodes, a single liver lesion, and a long interval between breast cancer diagnosis and liver metastasis. Decisions should be made by a multidisciplinary team.\u003c\/p\u003e\n\u003ch3\u003eWhat does a hazard ratio of 0.69 mean for my survival?\u003c\/h3\u003e\n\u003cp\u003eA hazard ratio of 0.69 means that at any given point during the follow-up period, patients who had liver resection were 31% less likely to die than those who did not have surgery. This is a clinically meaningful reduction in the risk of death over time, though it does not guarantee individual outcomes.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main limitations of this study on liver surgery for breast cancer metastases?\u003c\/h3\u003e\n\u003cp\u003eThe authors note that none of the 9 included studies were randomized, so selection bias is possible. There was significant variation between studies, and details on chemotherapy and other treatments were incomplete. No data on recurrence or quality of life was available. They emphasize the need for randomized trials to confirm these results.\u003c\/p\u003e\n\u003ch3\u003eWhy do doctors disagree about using liver surgery for breast cancer that has spread to the liver?\u003c\/h3\u003e\n\u003cp\u003eGuidelines differ: the ESO-ESMO consensus recommends surgery only in very selected cases, while NCCN guidelines do not list liver resection as a curative option. Also, fewer than 8% of patients with metastatic breast cancer have disease confined only to the liver, making it hard to know who benefits. This study aimed to address that gap.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor about liver surgery for breast cancer that spread to my liver?\u003c\/h3\u003e\n\u003cp\u003eAsk whether liver resection is an option for your specific situation. Discuss your tumor biology, hormone receptor and HER2 status, the extent of liver involvement, and whether cancer exists outside the liver. Also ask about your overall health and performance status, and how surgery would fit with systemic therapy. A multidisciplinary team should weigh benefits and risks.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e impact of liver resection on survival for patients with metastatic breast cancer\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Gavin G. Calpin, Matthew G. Davey, Pádraig Calpin, Ferdia Browne, Aoife J. Lowery, Michael J. Kerin\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e The Surgeon, Volume 21 (2023), pages 242–249\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication Details:\u003c\/strong\u003e Received May 26, 2022; accepted October 13, 2022; available online November 1, 2022. Published by Elsevier Ltd on behalf of the Royal College of Surgeons of Edinburgh and the Royal College of Surgeons in Ireland. This is an open access article under the CC BY-NC-ND license.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e This research received no external funding. All authors declared no conflicts of interest.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for informational purposes only and does not constitute medical advice. Patients should discuss their individual treatment options with their healthcare team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458366521500,"sku":null,"price":0.0,"currency_code":"JPY","in_stock":true}],"url":"https:\/\/diagnosticdetectives.tw\/products\/liver-surgery-for-breast-cancer-that-has-spread-to-the-liver-what-the-latest-research-shows","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}